Oncolinx's Debt Round

Oncolinx raised a round of funding on December 30, 2014.

Oncolinx is developing antibody-drug conjugates, which carry an Azonafide cytotoxin attached to an antibody specifically to tumor cells and not healthy cells, thereby avoiding many of the side effects…

Articles about Oncolinx's Debt Round: